Состояние проблемы разработки вакцин для специфической профилактики COVID-19

ПРЕПРИНТ

Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.

Бугоркова С. А.

2020-07-14

https://doi.org/10.21055/preprints-3111719

На сегодняшний день не вызывает сомнения важность решения вопроса с созданием эффективной и безопасной вакцины для борьбы с COVID-19. В обзоре представлены материалы по перспективным достижениям в разработке вакцин-кандидатов против SARS-CoV-2. Проанализирован текущий трек создаваемых вакцин-кандидатов против SARS-CoV-2 по данным на 08.07 2020 г. с позиции оценки их эффективности и безопасности. Выделены наиболее перспективные разработки, реализуемые в ближайшее время. Показано, что активное создание и оценка разрабатываемых вакцин против SARS-CoV-2 позволит иметь богатую альтернативу при выборе препарата по цене и эффективности и накопить потенциальный опыт для разработки вакцин против вновь появляющихся вирусов.

Ссылка для цитирования:

Бугоркова С. А. 2020. Состояние проблемы разработки вакцин для специфической профилактики COVID-19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111719

Список литературы

1. WHO Working Group – Target Product Profiles for COVID-19 Vaccines. 17 April 2020. https://www.who.int/publications/m/item/who-working-group-target-product-profiles-for-covid-19-vaccines

2. WHO. A coordinated global research roadmap: 2019 novel coronavirus.March 2020.R&DBlueprint. https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1

3. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Version 2. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMID: 32221306;

4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651

5. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11(12):1405–13. https://doi.org/10.1586/erv.12.126

6. A public health emergency of international concern over the global outbreak of novel coronavirus declared by WHO. Available at: https://www.who.int/dg/speeches/detail/whodirector-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)

7. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2001468

8. J.Corum, D. Grady, Sui-Lee Wee and C. Zimmerhttps Coronavirus Vaccine Tracker https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

9. Roujian Lu, Xiang Zhao, Juan Li , Peihua Niu , Bo Yang , Honglong Wu, Wenling Wang, Hao Song , Baoying Huang , Na Zhu, Yuhai Bi, Xuejun Ma , Faxian Zhan , Liang Wang , Tao Hu , Hong Zhou , Zhenhong Hu , Weimin Zhou , Li Zhao, Jing Chen , Yao Meng, Ji Wang , Yang Lin, Jianying Yuan, Zhihao Xie, Jinmin Ma , William J Liu, Dayan Wang, Wenbo Xu , Edward C Holmes , George F Gao , Guizhen Wu , Weijun Chen , Weifeng Shi , Wenjie Tan. Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8.

10. M.K. Smatti, A.A. Al Thani, H.M. Yassine Viral-induced enhanced disease illness. Front Microbiol. 2018;9: 2991 doi: 10.3389/fmicb.2018.02991

11. Ayato Takada, Heinz Feldmann, Thomas G. Ksiazek, and Yoshihiro Kawaoka. Antibody-Dependent Enhancement of Ebola Virus Infection. Journal of virology. 2003; 77 (13): 7539–7544. DOI: 10.1128/JVI.77.13.7539–7544.2003

12. M. Bolles, D. Deming, K. Long, S. Agnihothram, A. Whitmore, M. Ferris, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge J. Virol, 85 (2011), pp. 12201-12215

13. P. Hotez , M. E. Bottazzi , D. Corry The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement. Journal reference: Microbes and Infection 2020 DOI: 10.1016/j.micinf.2020.04.005

14. R. Carlson. CoronaVac SARS-CoV-2 Vaccine. https://www.precisionvaccinations.com/vaccines/coronavac-sars-cov-2-vaccine

15. Feng-Cai Zhu , Yu-Hua Li, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Jing-Xin Li, Shi-Po Wu , Bu-Sen Wang , Zhao Wang, Lei Wang, Si-Yue Jia , Hu-Dachuan Jiang , Ling Wang , Tao Jiang , Yi Hu , Jin-Bo Gou , Sha-Bei Xu , Jun-Jie Xu , Xue-Wen Wang , Wei Wang , Wei Chen. Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-In-Human TrialClinical Trial. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22

16. Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccines Immunother. 2014;10(3):648–58

17. Wen-Hsiang Chen, Ulrich Strych, Peter J Hotez, Maria Elena Bottazzi The SARS-CoV-2 Vaccine Pipeline: an Overview. Current Tropical Medicine Reports 2020; 7: 61–64

18. Lowe D. (2020). First results from Moderna’s coronavirus vaccine. In the pipeline; https://blogs.sciencemag.org/pipeline/archives/2020/05/18/first-results-from-modernas-coronavirus-vaccine

19. Trevor R. F. Smith, Ami Patel, Stephanie Ramos, Dustin Elwood, Xizhou Zhu, et. al.. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11:2601.

20. Helena Legido-Quigley , Nima Asgari, Yik Ying Teo, Gabriel M Leung , Hitoshi Oshitani , Keiji Fukuda, Alex R Cook , Li Yang Hsu , Kenji Shibuya , David Heymann. Are high-performing health systems resilient against the COVID-19 epidemic? Lancet, 2020. 395(10227): p. 848-850.

21. David Baud, Xiaolong Qi, Karin Nielsen-Saines, Didier Musso, Léo Pomar, Guillaume Favre. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis, 2020.

22. Remuzzi, A. and G. Remuzzi, COVID-19 and Italy: what next? Lancet, 2020.

23. Monia Makhoul, Houssein H. Ayoub, Hiam Chemaitelly, Shaheen Seedat, Ghina R Mumtaz, Sarah Al-Omari, Laith J. Abu-Raddad. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. Preprint medRxiv. doi: https://doi.org/10.1101/2020.04.19.20070805

24. Singh K., Mehta S. The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med. 2016; 62(1): 4–11.doi: 10.4103/0022-3859.173187.

25. Paustian T. A review of vaccine efforts against SARS-CoV-24; on Jul 11 2020. https://www.translatetheweb.com/?from=en&to=ru&ref=SERP&dl=en&rr=UC&a=https%3a%2f%2fwww.microbiologytext.com%2f6th_ed%2fnews%2fmessage%2fa-review-of-vaccine-efforts-against-sars-cov-2.

26. William A. Haseltine The Risks of Rushing a COVID-19 Vaccine. June 22, 2020. https://www.scientificamerican.com/article/the-risks-of-rushing-a-covid-19-vaccine/

27. Michelle M. Mello, Ross D. Silverman, Saad B. Omer Ensuring Uptake of Vaccines against SARS-CoV-2 The New England journal of medicine. 2020;nejm.org on July 13. https://www.nejm.org/doi/full/10.1056/NEJMp2020926.

ПРЕПРИНТ

ИНФОРМАЦИЯ О ПРЕПРИНТЕ